Design Therapeutics, Inc. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Design Therapeutics reported Q3 2026 net loss of $20.3M ($16.9M R&D, $5.3M G&A) on quarterly basis; nine-month net loss of $58.1M. Cash and securities totaled $208.6M as of September 30, 2026, down from $219.8M at year-end 2025. Company has four clinical programs: DT-216P2 (Friedreich ataxia Phase 1/2), DT-818 (myotonic dystrophy Phase 1), DT-168 (Fuchs dystrophy Phase 2 biomarker), and preclinical Huntington's disease candidate. Key milestones: registrational plan update Q4 2026, 12-week RESTORE-FA data Q1 2027, DT-818 data in 2027.
Why this rating
Routine quarterly disclosure. Company burning ~$22M/quarter; cash runway ~9.5 quarters adequate. No material deal, partnership, or clinical setback disclosed.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.